{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:04:51Z","timestamp":1763748291515,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000855","name":"University of Birmingham","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000855","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Modern antiviral treatments have high cure rates against the hepatitis C virus however, the high cost associated with branded medicines and diagnostic tests, have resulted in poor access for many low-income patients residing in low-and-middle-income countries. <jats:italic>Objective<\/jats:italic> This study aimed to evaluate the role of a patient assistance programme and generic medicines in improving access to treatment of low-income hepatitis C patients in a low-and-middle-income country. <jats:italic>Setting<\/jats:italic> A major teaching public hospital in Islamabad, Pakistan. <jats:italic>Methods<\/jats:italic> Hepatitis C patients who presented and enrolled for the patient assistance programme during 12\u00a0months (1st July 2015 and 30th June 2016) were included. Demography, prescription characteristics, the total costs of Hepatitis C treatment, medicine cost supported by the programme, out-of-pocket cost borne by the patient and average cost effectiveness ratio per sustained virologic response were calculated and compared for different generic and branded regimens. <jats:italic>Main outcome measure<\/jats:italic> cost contribution of patient assistance programme. <jats:italic>Results<\/jats:italic> A total of 349 patients initiated the treatment through the programme and of those 334 (95.7%) completed the prescribed treatment. There were 294 (88.02%) patients who achieved sustained virologic response. Patient assistance programme contributed medicines cost averaging 60.28\u201386.26% of the total cost of treatment ($1634.6) per patient. The mean (SE) cost per patient for generic option (Sofosbuvir\/Ribavirin) was the lowest [$658.36 (22.3) per patient, average cost effectiveness ratio\u2009=\u2009$720.1\/SVR] than branded option (Sovaldi\/Ribavirin) [$2218.66 (37.6) per patient, average cost effectiveness ratio\u2009=\u2009$2361.8\/SVR] of the three available treatment regimens. From patients\u2019 perspectives, the mean (SE) out-of-pocket cost was $296.9 (6.7) which primarily included diagnostic cost (69.9%) of the total cost. <jats:italic>Conclusions<\/jats:italic> Patient assistance programme, combined with generic brands of newer hepatitis C treatment offered a significant reduction in cost and widens access to hepatitis C treatment in low-and middle-income countries. However, substantial out-of-pocket costs of the treatment presents an important barrier for service access. There is a scope to widen such financial assistance programme to offer other costs attributed to patients, specifically for diagnosis, to widen service use in low-and-middle-income countries.<\/jats:p>","DOI":"10.1007\/s11096-020-01202-1","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T07:02:31Z","timestamp":1606546951000},"page":"958-968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme"],"prefix":"10.1007","volume":"43","author":[{"given":"Salamat","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tofeeq","family":"Ur-Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashhood","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayeed","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleri","family":"Lougher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sarfraz","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-6490","authenticated-orcid":false,"given":"Vibhu","family":"Paudyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,28]]},"reference":[{"key":"1202_CR1","unstructured":"World Health Organization (a) (WHO). Fact sheets\/Detail\/HC. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-c (2018). Accessed 12 Dec 2018."},{"key":"1202_CR2","unstructured":"Alavian S-M. HC virus infection: epidemiology, risk factors and prevention strategies in public health in IR IRAN. Gastroenterol Hepatol Bed Bench. 2009;3(1)."},{"issue":"9","key":"1202_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of HC virus infection. Lancet Infect Dis. 2005;5(9):558\u201367.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1202_CR4","doi-asserted-by":"publisher","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","volume":"13","author":"S Iyengar","year":"2016","unstructured":"Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for HC in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.","journal-title":"PLoS Med"},{"issue":"10","key":"1202_CR5","doi-asserted-by":"publisher","first-page":"e005694","DOI":"10.1136\/bmjopen-2014-005694","volume":"4","author":"P Roux","year":"2014","unstructured":"Roux P, Sagaon-Teyssier L, Lions C, Fugon L, Verger P, Carrieri M. HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. BMJ Open. 2014;4(10):e005694.","journal-title":"BMJ Open"},{"issue":"9859","key":"1202_CR6","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095\u2013128.","journal-title":"Lancet"},{"issue":"4","key":"1202_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of HC virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342.","journal-title":"Hepatology"},{"key":"1202_CR8","unstructured":"World Health Organization (b). Global report on access to HC treatment. Focus on overcoming barriers. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/250625\/WHO-HIV-2016.20-eng.pdf?sequence=1 (2016). Accessed 13 Oct 2018."},{"issue":"5","key":"1202_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4254\/wjh.v7.i5.806","volume":"7","author":"S Bansal","year":"2015","unstructured":"Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-HC virus therapy: a meta-analysis. World J Hepatol. 2015;7(5):806\u20138.","journal-title":"World J Hepatol"},{"issue":"6193","key":"1202_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1126\/science.1257737","volume":"345","author":"A Hill","year":"2014","unstructured":"Hill A, Cooke G. HC can be cured globally, but at what cost? Science. 2014;345(6193):141\u20132.","journal-title":"Science"},{"issue":"4","key":"1202_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/tmi.12837","volume":"22","author":"GS Cooke","year":"2017","unstructured":"Cooke GS. Scaling-up HCV treatment to achieve WHO targets by 2030. Trop Med Int Health. 2017;22(4):372\u20134.","journal-title":"Trop Med Int Health"},{"issue":"4","key":"1202_CR12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3748\/wjg.v22.i4.1684","volume":"22","author":"M Umer","year":"2016","unstructured":"Umer M, Iqbal M. HC virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol. 2016;22(4):1684\u20137.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1202_CR13","first-page":"4","volume":"41","author":"NS Raja","year":"2008","unstructured":"Raja NS, Janjua KA. Epidemiology of HC virus infection in Pakistan. J Micro Immun Infect. 2008;41(1):4\u20136.","journal-title":"J Micro Immun Infect"},{"key":"1202_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.antiviral.2015.01.004","volume":"119","author":"CS Graham","year":"2015","unstructured":"Graham CS, Swan T. A path to eradication of HC in low-and middle-income countries. Antivir Res. 2015;119:89\u201396.","journal-title":"Antivir Res"},{"issue":"9885","key":"1202_CR15","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/S0140-6736(13)60813-2","volume":"381","author":"S Nishtar","year":"2013","unstructured":"Nishtar S, Bhutta ZA, Jafar TH, Ghaffar A, Akhtar T, Bengali K, et al. Health reform in Pakistan: a call to action. Lancet. 2013;381(9885):2291\u20137.","journal-title":"Lancet"},{"key":"1202_CR16","doi-asserted-by":"crossref","unstructured":"Chaudhry TT, Nabeel F. Microinsurance in Pakistan: progress, problems, and prospects. Lahore J Ecol 2014;18(SE):335\u2013374.","DOI":"10.35536\/lje.2013.v18.isp.a15"},{"issue":"4","key":"1202_CR17","first-page":"407","volume":"23","author":"LL Zullig","year":"2017","unstructured":"Zullig LL, Wolf S, Vlastelica L, Shankaran V, Zafar SY. The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm. 2017;23(4):407\u201311.","journal-title":"J Manag Care Spec Pharm"},{"key":"1202_CR18","unstructured":"Kaplan K. Low-and middle-income countries defuse HC. HIV Treat Bull. http:\/\/i-base.info\/htb\/21506 (2013). Accessed 15 June 2018."},{"issue":"6","key":"1202_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/apt.13081","volume":"41","author":"Z Younossi","year":"2015","unstructured":"Younossi Z, Park H, Saab S, Ahmed A, Dieterich D, Gordon S. Cost-effectiveness of all-oral ledipasvir\/sofosbuvir regimens in patients with chronic HC virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41(6):544\u201363.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1202_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40199-016-0151-z","volume":"24","author":"S Ahmadiani","year":"2016","unstructured":"Ahmadiani S, Nikfar S. Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective. DARU J Pharm Sci. 2016;24(1):13.","journal-title":"DARU J Pharm Sci"},{"key":"1202_CR21","doi-asserted-by":"crossref","unstructured":"Stadhouders N, Kruse F, Tanke M, Koolman X, Jeurissen P. Effective healthcare cost-containment policies: a systematic review. Health Policy. 2018.","DOI":"10.1016\/j.healthpol.2018.10.015"},{"issue":"17","key":"1202_CR22","first-page":"347","volume":"23","author":"MR Khan","year":"2009","unstructured":"Khan MR, Ali U. An analysis of individual finance assistance program under the Pakistan Bait-ul-Maal. Stat Sci. 2009;23(17):347\u201353.","journal-title":"Stat Sci"},{"issue":"1","key":"1202_CR23","first-page":"2","volume":"1","author":"D Pranam","year":"2013","unstructured":"Pranam D. Zakat as a measure of social justice in Islamic finance: an accountant\u2019s overview. J Emerg Econ Islam Res. 2013;1(1):2\u20135.","journal-title":"J Emerg Econ Islam Res"},{"key":"1202_CR24","unstructured":"Sayeed A, editor. Social protection in Pakistan: concept, situation analysis and the way forward. Proceedings of a Joint Seminar Organized by the Planning Commission, ILO and UNDP on Employment-based Poverty Reduction Strategy for Decent Work in Pakistan Pakistan Institute of Development Economics Islamabad. http:\/\/researchcollective.org\/Documents\/Social_Protection_Way_Forward.pdf (2004). Accessed 14 Dec 2018."},{"issue":"4","key":"1202_CR25","first-page":"355","volume":"4","author":"M Ali","year":"2013","unstructured":"Ali M, Rafi S. Medical social work in Pakistan: a multi-model approach to collaborative practice in health care settings. Acad Res Int. 2013;4(4):355.","journal-title":"Acad Res Int"},{"key":"1202_CR26","unstructured":"Maal PBu. Criteria for HC patients 2017. http:\/\/www.pbm.gov.pk\/forms.html (2017). Accessed 10 Aug 2017."},{"key":"1202_CR27","doi-asserted-by":"crossref","unstructured":"Liver EAfTSoT. EASL recommendations on treatment of HC 2016. J Hepatol. 2017;66(1):153.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"1202_CR28","unstructured":"Pharmaguide. 24 ed: Pharmaguide publishing company, Paramount; 2016. https:\/\/www.epharmaguide.com\/ (2016). Accessed 20 June 2016."},{"key":"1202_CR29","unstructured":"Regional Transport Authority I. public transport; fare 2016. https:\/\/ictadministration.gov.pk\/ (2016). Accessed 20 June 2016."},{"key":"1202_CR30","unstructured":"Division F. Annual budget statement. In: Division F, editor. Federal budget 2015\u20132016. http:\/\/www.finance.gov.pk\/budget\/abs_2015_16.pdf (2018). Accessed 20 June 2018."},{"key":"1202_CR31","doi-asserted-by":"crossref","unstructured":"Zare F, Fattahi MR, Sepehrimanesh M, Safarpour AR. Economic burden of HC virus infection in different stages of disease: a report from Southern Iran. Hepat Mon. 2016;16(4).","DOI":"10.5812\/hepatmon.32654"},{"key":"1202_CR32","unstructured":"Trask LS, Chapter L. Pharmacoeconomics: principles, methods, and applications. In: Pharmacotherapy: a pathophysiologic approach 8th ed. New York: McGraw-Hill Global Education Holdings. http:\/\/accesspharmacy.mhmedical.com\/content.aspx (2011). Accessed 2 Dec 2018."},{"key":"1202_CR33","doi-asserted-by":"publisher","DOI":"10.1201\/9781420084405","volume-title":"Pharmacoeconomics: from theory to practice","author":"RJ Arnold","year":"2016","unstructured":"Arnold RJ. Pharmacoeconomics: from theory to practice. Boca Raton: CRC Press; 2016."},{"key":"1202_CR34","unstructured":"Pakistan NBoP. Rate Sheet-NBP-National Bank of Pakistan 2016 [updated 29.01.2016. https:\/\/www.nbp.com.pk\/RateSheet\/index.aspx (2016). Accessed 11 June 2018."},{"issue":"7","key":"1202_CR35","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of direct-acting antiviral combination for patients with HC virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150(7):1590\u20138.","journal-title":"Gastroenterology"},{"issue":"1","key":"1202_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","volume":"65","author":"NK Martin","year":"2016","unstructured":"Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016;65(1):17\u201325.","journal-title":"J Hepatol"},{"key":"1202_CR37","unstructured":"Reich MR. Public-private partnerships for public health. Publ Priv Partnersh Publ Health. 2002;1\u201318."},{"key":"1202_CR38","unstructured":"World Health Organization (c). Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. https:\/\/www.google.com\/search?q=World+Health+Org.+2009.+Global+tuberculosis+control%3A+epidemiology%2C+strategy%2C+financing%3A+WHO+report+2009.+&ie=utf-8&oe=utf-8&client=firefox-b (2009). Accessed 20 Dec 2018."},{"key":"1202_CR39","unstructured":"World Health Organization (d). Important new agreement on HC treatment signed. https:\/\/medicinespatentpool.org\/mpp-media-post\/the-medicines-patent-pool-signs-licence-with-abbvie-to-expand-access-to-key-hepatitis-c-treatment-glecaprevirpibrentasvir\/ (2018). Accessed 20 Dec 2018."},{"key":"1202_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13027","volume":"36","author":"T Asselah","year":"2016","unstructured":"Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of HC virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36:47\u201357.","journal-title":"Liver Int"},{"key":"1202_CR41","unstructured":"Wikipedia. Economy of Pakistan. https:\/\/en.wikipedia.org\/wiki\/Economy_of_Pakistan (2018). Accessed 16 Dec 2018."},{"issue":"4","key":"1202_CR42","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/pubmed\/fds105","volume":"35","author":"L Ti","year":"2013","unstructured":"Ti L, Kaplan K, Hayashi K, Suwannawong P, Wood E, Kerr T. Low rates of HC testing among people who inject drugs in Thailand: implications for peer-based interventions. J Pub Health. 2013;35(4):578\u201384.","journal-title":"J Pub Health"},{"key":"1202_CR43","unstructured":"World Health Organization (e). WHO urges countries to scale up HC treatment 2018. https:\/\/www.who.int\/hepatitis\/news-events\/hep-c-access-report-2018-story\/en\/ (2018). Accessed 12 Dec 2018."},{"key":"1202_CR44","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/jech-2015-205454","volume":"70","author":"M Hellard","year":"2016","unstructured":"Hellard M, Sacks-Davis R, Doyle J. HC elimination by 2030 through treatment and prevention: think global, act in local networks. J Epidemiol Commun Health. 2016;70:1151\u20134.","journal-title":"J Epidemiol Commun Health"},{"key":"1202_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11096-020-00994-6","volume":"42","author":"S Ali","year":"2020","unstructured":"Ali S, Ur-Rehman T, Lougher E, Mutimer D, Ali M, Paudyal V. Impact of HIV and chronic kidney disease comorbidities on HC treatment choices, drug-drug interactions and HC cure. Int J Clin Pharm. 2020;42:515\u201326.","journal-title":"Int J Clin Pharm"},{"key":"1202_CR46","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2147\/PPA.S224937","volume":"13","author":"S Ali","year":"2019","unstructured":"Ali S, Ali M, Paudyal V, Rasheed F, Ullah S, Haque S, Ur-Rehman T. A randomized controlled trial to assess the impact of clinical pharmacy interventions on treatment outcomes, health related quality of life and medication adherence among HC patients. Patient Pref Adher. 2019;13:2089\u2013100.","journal-title":"Patient Pref Adher"},{"issue":"685","key":"1202_CR47","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.3399\/bjgp19X704609","volume":"69","author":"M Bowen","year":"2019","unstructured":"Bowen M, Marwick S, Marshall T, Saunders K, Burwood S, Yahyouche A, et al. Multi-morbidity and emergency department visits by a homeless population: a database study in specialist general practice. Br J Gen Pract. 2019;69(685):e515\u201325.","journal-title":"Br J Gen Pract"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01202-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:27:31Z","timestamp":1628537251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01202-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2020,11,28]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a part of PhD Project of SA who was awarded a 6\u00a0months scholarship by Higher Education Commission of Pakistan to visit and collaborate research at University of Birmingham, UK. No other funding is involved in or during the conduct of study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflict of interests that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The original files, datasets used and analysed in the current study are available from the custodian of the data: tofeeq.urrehman@qau.edu.pk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data statement section"}}]}}